BioSpace News Archive

Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced the grant of inducement stock options exercisable for an aggregate of 23,000 shares of Albireo’s common stock. The stock options are exercisable at a price of $32.90 per share, the closing price of Albireo’s common stock on September 28, 2020, the grant date, and were granted as inducements material to the

Aurinia Pharmaceuticals Inc. announced that the Company’s Compensation Committee granted 9 new employees non-qualified stock options to purchase an aggregate of 96,000 common shares, at a per share exercise price of $14.73 USD, the closing trading price on September 30, 2020.

Presentations to include follow-up MINDACT study data and evaluations on the use of MammaPrint to guide treatment decisions in lobular cancers and for screen-detected breast cancers versus interval-detected breast cancers IRVINE, Calif. , Oct. 2, 2020 /PRNewswire/ -- Agendia, Inc., a world leader in precision oncology for breast cancer, today announced the presentation o

Sartorius Stedim Biotech, a leading international partner of the biopharmaceutical industry, announced it has entered into a definitive agreement to merge with purification specialist BIA Separations in a transaction totaling 360 million euros of which 240 million euros will be paid in cash and 120 million euros in Sartorius Stedim Biotech shares.

Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that Quidel has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) to market its Sofia® 2 Flu + SARS Antigen FIA,

Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA, today announced that its Signatera molecular residual disease (MRD) test will be used in the DARE study, a multi-center clinical trial of palbociclib (IBRANCE®), a CDK4/6 inhibitor developed by Pfizer for the treatment of HR-positive, HER2-negative ad

What’s New: Today, Intel Federal LLC announced a three-year agreement with Sandia National Laboratories (Sandia) to explore the value of neuromorphic computing for scaled-up computational problems

OnLume Inc., an early stage medical imaging company with unique technology for improving surgical precision, has been awarded a substantial grant from the U.S. National Institutes of Health (NIH)’s National Cancer Institute (NCI) to advance development of its proprietary device for Fluorescence-Guided Surgery (FGS). OnLume has developed novel FGS imaging technology to illuminate critical anatomy in real-time during sur

As part of its continued efforts to connect healthcare specialists around the world with clinically relevant news and information, expert perspectives, and continuing education, HMP Global, a leading healthcare event and education company, today announced the launch of the Gastroenterology Learning Network.

ENDRA Life Sciences Inc. (“ENDRA”) (NASDAQ:NDRA), the pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced that management will present at the 4th Annual H.C. Wainwright NASH Investor Conference.